Event Details
July 24, 2015
Description
Investor Relations Conference Call on Praluent for the financial community.
Participants (3)
| Name | Type | Mentions | |
|---|---|---|---|
| Financial Community | person | 0 | View Entity |
| Regeneron | organization | 22 | View Entity |
| Sanofi | organization | 26 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_026365.jpg
This document is a press release from pharmaceutical companies Sanofi and Regeneron regarding their cholesterol drug, Praluent (alirocumab). It announces the drug's approval based on clinical trial data, its U.S. price of $40 per day, and the launch of patient support programs. The release also advertises an investor relations conference call scheduled for July 24, 2015, and notes a pending marketing authorization decision in the European Union.
Related Events
Events with shared participants
Investor Relations Conference Call hosted by Sanofi and Regeneron to discuss Praluent.
2015-07-24 • Teleconference / Webcast
Trading of Regeneron shares was halted pending news.
Date unknown
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
ODYSSEY clinical trial program.
2025-12-01
Investor Relations Conference Call on Praluent hosted by Sanofi and Regeneron
2015-07-24 • Conference Call / Webcast
Expected final decision by European Commission on Marketing Authorization Application
2015-09-01 • European Union
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event